Shanghai, China , Jan 25, 2021 – Asieris Pharmaceuticals announced today that Dr. Yong Xue has been appointed Chief Medical Officer and Mr. Xinming Jiang has been appointed Head of Sales and Marketing, both of them reporting directly to Founder, CEO Dr. Kevin Pan.
Dr.Yong Xue has more than 20 years experiences in global clinical development and medical affairs in leading pharmaceutical companies. He also has 15 years of experiences in the clinical practice, academic research,clinical development and medical affairs of new drugs for urology and related diseases. He used to be responsible for the clinical and medical affairs of urinary products at Yamanouchi Europe (now is Astellas), and participated in the development and life-cycle management of of uro-oncological and non-oncological drugs, such as Harnal (tamsolusin for benigh prostatic hyperplasia, BPH), Vesicare (solifenacin for overactive bladder, OAB).
Dr.Yong Xue also served as Global Clinical Research and Medical Director at Genzyme and Sanofi for 15 years. He closely collaborated with regulatory and other functional units, his team successfully conducted clinical trials of several new drugs, such as Cerdelga (eliglustat), and got the product commercialized in over a dozen of countries worldwide.
In addition, as global medical and clinical lead, Dr.Yong Xue and his team obtained full approval of Aldurazyme by EMA after 12 years’ conditional approval for the marketing authorization. Dr.Yong Xue has a wealth of experiences in clinical development, registration and post-marketing clinical research of both biologics and small molecules in Europe, America, Japan and major emerging countries, including China, for both strategic guidance and execution.
Prior to Asieris, he served as Chief Medical Officer and Senior Vice President at Sperogenix Therapeutics. Dr.Yong Xue holds a medical degree from Beijing Medical University (now is Medical and Health Science Center of Peking University) and a Ph.D. in cell biology from University Medical Center Nijmegen (UMCN, the Netherlands).
His clinical practice and academic research include residency in urology at Beijing Friendship Hospital, a teaching hospital of Capital Medical University, Beijing; research fellow at Department of Urology, Radboud Hospital (UMCN). Dr. Xue Yong’s academic memberships include American Urological Association (AUA), European Association of Urology (EAU). His publications include a book on prostaticembryo development and related diseases, and over 25 papers on peer-reviewed international journals as either the first author, corresponding author, or major contributor.
Mr. Jiang brings more than a decade of experience in the pharmaceutical industry with expertise in commercial launch of new product and market development of mature products. Prior to Asieris, Mr. Jiang served as National Sales and Marketing Director at Pierre Fabre heading up the Oncology Business Unit, SFE and training in China. During his tenure, he has successfully driven the rapid growth of oncology business and leading the preparation for the launch of new in China for many years.
Before that he served as Marketing Director, Regional Manager, and Sales Director Roche for 8 years, participated in the strategy development and execution of Herceptin and Xeloda, and successfully launch the gastric cancer as the new indication of Herceptin in China, he’s experienced in building, motivating and managing high performance marketing teams. Mr. Jiang also served many multinational pharmaceutical companies, such as Baxter, Pfizer. He graduated from Shanghai Jiaotong University with a Bachelor’s Degree in Clinical Medicine and he also has more than 8 years experience as a clinician.
“We are very pleased to have Dr. Xue Yong and Mr. Jiang Xinming join us,” said Dr. Kevin Pan, Founder and CEO of Asieris. “After ten years of development, Asieris, as an innovative pharmaceutical company focusing on genitourism and related diseases, has entered into a new stage of integrating research, production and marketing. It is momentous for all of us ,we believe they two executives will accelerate the global clinical development and commercialization of our product pipeline with their rich experience, and enabling our products to help the patients in China and worldwide.”
